<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02846506</url>
  </required_header>
  <id_info>
    <org_study_id>CR108200</org_study_id>
    <secondary_id>28431754DIA1075</secondary_id>
    <nct_id>NCT02846506</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants</brief_title>
  <official_title>A Single-Dose, Open-Label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) 1 x (150 mg/500 mg) With Respect to the Metformin XR Tablet (Locally Sourced From Canada [GLUMETZA, 1 x 500 mg]) Coadministered With Canagliflozin (1 x 100 mg + 1 x 50 mg) in Healthy Fed and Fasted Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate bioequivalence of the metformin component of the&#xD;
      Fixed Dose Combination (FDC) tablet compared with the metformin Extended Release (XR) tablet&#xD;
      co-administered with canagliflozin in healthy fed and fasted participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Metformin</measure>
    <time_frame>Pre-dose, 0.5 hour (hr), 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, hr post-dose on Day 1; 24 hr post-dose on Day 2</time_frame>
    <description>The Cmax is the maximum observed plasma concentration of metformin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time 0 to The Time of the Last Observed Quantifiable Concentration (AUClast) of Metformin</measure>
    <time_frame>Pre-dose, 0.5 hour (hr), 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, hr post-dose on Day 1; 24 hr post-dose on Day 2</time_frame>
    <description>The AUClast is the area under the plasma concentration-time curve from time 0 to the time of the last observed quantifiable concentration (Clast).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time 0 to Infinite Time [AUC (0-infinity)] of Metformin</measure>
    <time_frame>Pre-dose, 0.5 hour (hr), 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, hr post-dose on Day 1; 24 hr post-dose on Day 2</time_frame>
    <description>The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>Day -1 to End of study (up to 58 Days)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence ADBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment A (1 canagliflozin tablet 100 milligram (mg) and 1 canagliflozin tablet 50 mg along with 1 Extended Release (XR) tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 XR fixed dose combination [FDC] tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg and metformin (XR) 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence BACD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence CBDA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence DCAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]</intervention_name>
    <description>Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.</description>
    <arm_group_label>Treatment Sequence ADBC</arm_group_label>
    <arm_group_label>Treatment Sequence BACD</arm_group_label>
    <arm_group_label>Treatment Sequence CBDA</arm_group_label>
    <arm_group_label>Treatment Sequence DCAB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin 50 mg</intervention_name>
    <description>Participants will receive canagliflozin 50 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.</description>
    <arm_group_label>Treatment Sequence ADBC</arm_group_label>
    <arm_group_label>Treatment Sequence BACD</arm_group_label>
    <arm_group_label>Treatment Sequence CBDA</arm_group_label>
    <arm_group_label>Treatment Sequence DCAB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin 100 mg</intervention_name>
    <description>Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.</description>
    <arm_group_label>Treatment Sequence ADBC</arm_group_label>
    <arm_group_label>Treatment Sequence BACD</arm_group_label>
    <arm_group_label>Treatment Sequence CBDA</arm_group_label>
    <arm_group_label>Treatment Sequence DCAB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Extended Release (XR)</intervention_name>
    <description>Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.</description>
    <arm_group_label>Treatment Sequence ADBC</arm_group_label>
    <arm_group_label>Treatment Sequence BACD</arm_group_label>
    <arm_group_label>Treatment Sequence CBDA</arm_group_label>
    <arm_group_label>Treatment Sequence DCAB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Contraceptive use by men or women should be consistent with local regulations&#xD;
             regarding the use of contraceptive methods for participant participating in clinical&#xD;
             studies&#xD;
&#xD;
          -  Before randomization, a woman must be either Not of childbearing potential or of&#xD;
             childbearing potential and agrees to use a highly effective method of contraception&#xD;
             (failure rate of less than [&lt;]1 percent [%] per year when used consistently and&#xD;
             correctly) throughout the study&#xD;
&#xD;
          -  All women must have a negative urine pregnancy test at Screening and on Day -1 of each&#xD;
             Treatment Period&#xD;
&#xD;
          -  Body mass index (BMI) (weight [kg]/height^2 [m]2) between 18 and 30 kg/m^2&#xD;
             (inclusive), and body weight not less than 50 kilogram (kg)&#xD;
&#xD;
          -  Blood pressure (an average of 3 measurements done after the participant is sitting for&#xD;
             5 minutes and with at least 5 minutes between measurements) between 90 and 140 mmHg,&#xD;
             inclusive, systolic and no higher than 90 (Millimeter of mercury) mmHg diastolic at&#xD;
             Screening or Day -1 of each Treatment Period&#xD;
&#xD;
          -  Normal renal function evidenced by estimated glomerular filtration rate (eGFR) &gt;=90&#xD;
             mL/min/1.73m2 using the Modification of Diet in Renal Disease Study (MDRD) equation as&#xD;
             defined in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of or current clinically significant medical illness including (but not&#xD;
             limited to) cardiac arrhythmias or other cardiac disease, hematologic disease,&#xD;
             coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid&#xD;
             abnormalities, significant pulmonary disease, including bronchospastic respiratory&#xD;
             disease, diabetes mellitus, renal or hepatic insufficiency, thyroid disease,&#xD;
             neurologic or psychiatric disease, infection, or any other illness that the&#xD;
             investigator considers should exclude the participant or that could interfere with the&#xD;
             interpretation of the study results&#xD;
&#xD;
          -  Clinically significant abnormal values for hematology, clinical chemistry, or&#xD;
             urinalysis as assessed by the investigator at Screening or Day -1 of the first&#xD;
             Treatment Period&#xD;
&#xD;
          -  Clinically significant abnormal physical examination, vital signs, or 12 lead&#xD;
             electrocardiogram (ECG) (Screening only) as assessed by the investigator at Screening&#xD;
             or on Day -1 of the first Treatment Period as deemed appropriate by the investigator&#xD;
&#xD;
          -  Use of any prescription or nonprescription medication (including vitamins and herbal&#xD;
             supplements), except for acetaminophen, hormonal contraceptives and hormonal&#xD;
             replacement therapy within 14 days before the first dose of the study drug is&#xD;
             scheduled&#xD;
&#xD;
          -  History of, or a reason to believe a participant has a history of drug or alcohol&#xD;
             abuse within the past 5 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>July 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2016</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

